NVVE vs TSLA

NVVE exhibits extreme financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from negative equity (Price/Book of -0.27) and catastrophic profitability metrics, including an ROE of -5084.87% and negative gross margins. A devastating 98.3% decline in share price over the last year, coupled with a 52-week high of $142.00 versus a current price of $0.67, suggests a total collapse in investor confidence. The lack of an Altman Z-Score and Graham Number further confirms that the company does not meet the minimum thresholds for solvency or defensive valuation.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.